Vertex Pharmaceuticals (VRTX) Surpasses Market Returns: Some Facts Worth Knowing

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $385.74, moving +1.01% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.59%. Elsewhere, the Dow saw an upswing of 0.65%, while the tech-heavy Nasdaq appreciated by 0.44%. The stock of drugmaker has fallen by 2.6% in the past month, lagging the Medical sector's loss of 0.94% and the S&P 500's gain of 2.72%.The investment community will be closely monitoring the performance of Vertex Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of $4.56, marking a 4.11% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $3.04 billion, reflecting a 9.8% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $17.98 per share and revenue of $11.98 billion, indicating changes of +4180.95% and +8.75%, respectively, compared to the previous year. Any recent changes to analyst estimates for Vertex Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now. In terms of valuation, Vertex Pharmaceuticals is presently being traded at a Forward P/E ratio of 21.24. This denotes a premium relative to the industry average Forward P/E of 18.92. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 98, putting it in the top 40% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks